PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma
Yael Babichev(Mount Sinai Hospital), Rebecca A. Gladdy(Lunenfeld-Tanenbaum Research Institute)
Cited by 53
Related Papers
Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group
|Annals of Surgical Oncology|2021|243
Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma
|Annals of Surgery|2022|138
Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival
|Nature Communications|2021|64
Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15 years
|Annals of Surgical Oncology|2020|56
Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms
|European Journal of Cancer|2021|32